

FOR IMMEDIATE RELEASE

ABITEC Corporation acquires Larodan AB Research Grade Lipids

Columbus, OH – July 8, 2020

ABITEC Corporation, an ABF Ingredients company, announced today that it has acquired Larodan AB, a manufacturer and international marketer of state of the art, high-purity research grade lipids. This strategic acquisition will expand ABITEC's functional lipid product offerings and scientific capabilities to better serve the pharmaceutical, nutritional and industrial market sectors.

Located at the globally recognized Karolinska Institute in Stockholm, Sweden, Larodan is known for its outstanding product quality, customer-friendly approach and extensive collaborations with academic and industrial researchers. "Larodan is a world leader in the field of analytical-grade lipids and their scientific capabilities will not only expand ABITEC's technical expertise but will also provide us with a strategic R&D location in Europe. The Larodan team has done an exceptional job in the development, manufacturing and global commercialization of their unique and highly specialized lipid reagents and we are thrilled to have them join the ABITEC team. We share a common passion for innovation and lipids, and I look forward to us working together to grow and expand their brand in the US markets and across the globe," said Jeff Walton, CEO of ABITEC. "The acquisition will undoubtedly bring ABITEC to the forefront of the high-purity lipid market.

It will also advance ABITEC into the field of Lipidomics which has the potential to offer researchers unparalleled capabilities to identify the numerous applications of lipids across a vast spectrum of health and disease states at the chemical level. Together, the companies will create a global science-based organization that will use product innovation to propel ABITEC's scientific and commercial interests to new heights. "We are very happy to find a new home with ABITEC, with whom we share a deep interest in lipids. Together we can immediately offer a more comprehensive service to our American customers including, larger volumes and GMP grades," said Fredrik Lindgren, selling shareholder and continuing Managing Director of Larodan.

About ABITEC Corporation

ABITEC Corporation is part of ABF Ingredients and is headquartered in Columbus, Ohio, US with two manufacturing sites in the Midwest. ABITEC specializes in the manufacturing and distribution of specialty lipid ingredients for use in the pharmaceutical, nutraceutical, and specialty chemical markets. In addition, ABITEC offers contract and toll manufacturing services for customers looking to develop and manufacture new oleochemical molecules, blend, or toll-manufacture an established product.



ABITEC's trademarked specialty ingredients include Capmul®, Captex®, Caprol®, Acconon®, Sterotex®, Nutri Sperse®, Hydro~Kote® and Pureco®. Through our world-class technical, scientific, regulatory, and manufacturing expertise, we deliver the highest quality lipid solutions in solubilization, emulsification and lubrication. All ABITEC ingredients are produced in the USA.

About ABF Ingredients

ABF Ingredients is a division of Associated British Foods plc that focuses on high value ingredients for both food and non-food areas and comprises a range of ingredient companies which include AB Enzymes, Ohly, PGP International, and SPI Pharma. The group has established strong market positions in cereal specialties, enzymes, esters, extruded ingredients, specialty lipids, specialty powders, specialty flours, yeast extracts worldwide.

About Larodan AB

Larodan develops, manufactures and markets a comprehensive range of high purity lipids for the international market. They serve customers throughout the world, directly and in collaboration with highly competent distribution partners. Their aim is to be the optimal partner for lipid related research, irrespective of the customer's need or location.

For further information, please contact:

Amanda Coulter

Manager: Marketing Research and Communications

614-429-6453 | acoulter@abiteccorp.com

www.abiteccorp.com

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond our control. We caution you that the forward-looking information presented in this press release is not a guarantee of future events, and that actual events may differ materially from those made in or suggested by the forward-looking information contained in this press release. In addition, forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "plan," "seek," "comfortable with," "will," "expect," "intend," "estimate," "anticipate," "believe" or "continue" or the negative thereof or variations thereon or similar terminology. Any forward-looking information presented herein is made only as of the date of this press release, and we do not undertake any obligation to update or revise any forward-looking information to reflect changes in assumptions, the occurrence of unanticipated events, or otherwise.